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Investigation of low 5-year relative survival for breast cancer
in a London cancer network
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BACKGROUND: Breast cancer 5-year relative survival is low in the North East London Cancer Network (NELCN).
METHODS: We compared breast cancer that was diagnosed during 2001–2005 with that in the rest of London.
RESULTS: North East London Cancer Network women more often lived in socioeconomic quintile 5 (42 vs 21%) and presented
with advanced disease (11 vs 7%). Cox regression analysis showed the survival difference (hazard ratio: 1.27, 95% confidence interval
(CI): 1.15–1.41) reduced to 1.00 (95% CI: 0.89–1.11) after adjustment for age, stage, socioeconomic deprivation, ethnicity and
treatment. Major drivers were stage and deprivation. Excess mortality was in the first year.
CONCLUSION: Late diagnosis occurs in NELCN.
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Women living in socioeconomically deprived areas have a lower
incidence of breast cancer (Shack et al, 2008), but a lower survival
than those in affluent areas (Coleman et al, 2004). Variation in
survival between English health authority areas is partly explained
by their differing levels of deprivation (Mullee et al, 2004). Women
from Black Caribbean and Black African ethnic groups have a
lower incidence of breast cancer, but a lower survival than White
women (Jack et al, 2009). These inequalities deserve investigation
to identify factors amenable to intervention. For example, lower
survival in one Swedish health district appeared to be because of a
lower intensity of diagnostic tests influencing accurate staging and
the treatment women received (Eaker et al, 2005). Investigations
within English regions found that women living in deprived areas
presented more often with advanced disease (Adams et al, 2004;
Downing et al, 2007; Cuthbertson et al, 2009; Wishart et al, 2010).
The lower survival of women from Black ethnic groups in South
East England was largely explained by more advanced disease and
socioeconomic deprivation (Jack et al, 2009).
This study investigates low breast cancer survival in North East
London Cancer Network (NELCN). For the period 2001–2005,
the 5-year relative survival was 75% (95% confidence interval (CI):
73.5–76.9) vs 79% (CI: 78.3–79.7) for London as a whole (Thames
Cancer Registry, 2007b). North East London Cancer Network
was also a low outlier for 1-year relative survival in England
(National Cancer Intelligence Network, 2008). Our objectives were
(1) to investigate whether differences in demographic, clinical or
treatment characteristics between NELCN women and the rest
of London explained this survival difference and (2) to identify
clinical or public health approaches to improve survival.
MATERIALS AND METHODS
Setting and hypotheses
NELCN covers a population of 1.5 million and is the most deprived
of the London cancer networks. Informed by recent reports
(Thames Cancer Registry, 2007a; Bowen et al, 2008; Greater
London Authority, 2008), and clinical and public health experi-
ence, a multi-disciplinary team developed the following hypotheses
to explain low survival: (1) low breast screening coverage led to a
lower proportion of screen-detected cancers, (2) the diverse
population included women from ethnic groups presenting with
poorer prognosis cancers and (3) a higher proportion of patients
lived in socioeconomically deprived areas.
Data
The Thames Cancer Registry has received information on screen-
detected breast disease from local screening programmes since
1998. We checked and extracted data on London women within the
screening age group 50–64 years. We also extracted data on 3773
women of all ages diagnosed with invasive breast cancer resident
in NELCN and on 17 059 women resident in the rest of London
during 2001–2005. Self-assigned ethnicity information was
obtained from Hospital Episode Statistics data, which includes
ethnicity codes, as defined by the 1991 and 2001 censuses. Data for
these years were linked to the Registry records and used to assign
women to the categories White, Black, Asian, Chinese, Mixed and
Other. Using postcode of residence at diagnosis, each woman was
also assigned to a lower super output area and categorized to a
quintile of deprivation using the Income Domain of the Index of
Multiple Deprivation (Neighbourhood Renewal Unit, 2004).The
Registry relies on data on disease stage recorded in individual
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medical records. This information is not always complete and for
this study, all available Registry data on tumour size, lymph nodes
or distant metastases were reviewed and used to assign a simplified
TNM stage to each patient (Linklater and Møller, 2005). Data on
whether the patient received surgery, chemotherapy, radiotherapy
and hormonal treatment within the first 6 months after their
diagnosis were also extracted.
Analyses
As screen-detected cancers are more likely to be in earlier disease
stage, the proportions of these cases in the screening age group for
NELCN and the rest of London were compared. Five-year relative
survivals for the period 2001–2005, comparing the survival of
NELCN women with other London women for each of the screen-
detected and non-screen-detected cancer diagnosed 1998–2005,
were calculated. The age, socioeconomic deprivation, ethnicity,
disease stage and treatment of women resident in NELCN and
diagnosed during 2001–2005 were then compared with those in
the rest of London. To assess influences on NELCN breast cancer-
specific survival, we fitted Cox regression models, adjusting
sequentially for age, stage, socioeconomic deprivation, ethnicity
and treatment, comparing breast cancer-specific survival in
NELCN women to all others in London. Finally, to determine the
period in which excess mortality might be occurring, Kaplan–
Meier survival curves for NELCN were constructed comparing it
with the rest of London. We then redrew these survival curves for
women who had already survived 1 year after diagnosis.
RESULTS
Survival of women with screen-detected and non-screen-
detected breast cancer in NELCN and the rest of London
for the period 2001–2005
The proportion of NELCN women in the 50–64-year age group
with screen-detected disease was slightly higher than for the rest of
London (46 vs 43%). The 5-year relative survival for the period
2001–2005 of NELCN women with screen-detected disease was not
significantly lower than those in the rest of London. However, the
survival of NELCN women with non-screen detected cancer was
lower (75.4% (CI: 72.0–78.8) vs 80.3% (CI: 78.9–81.5)). The
proportions of screen-detected disease suggest that low screening
uptake during 2001–2005 was not driving the overall NELCN
survival difference. However, the lower survival for those with
non-screen-detected disease suggests a group of NELCN women
presenting with more advanced or aggressive disease.
Characteristics of NELCN women compared with those
in the rest of London
Table 1 shows the characteristics of all women resident in NELCN
and diagnosed with breast cancer between 2001 and 2005
compared with those in the rest of London. Age and ethnicity
did not differ substantially, but NELCN women were more likely to
be living in the most deprived areas (quintile 5) (42 vs 21%). North
East London Cancer Network women were also more likely to be
diagnosed with stage 4 disease (metastases; 11 vs 7%) and were less
likely to receive radiotherapy (25 vs 31%).
Contribution of case mix factors to the lower survival
in NELCN
Table 2 shows the Cox proportional regression analysis. The
hazard ratio (relative risk of mortality) for patients in NELCN was
1.27. After adjustment for age, this risk reduced slightly to 1.23.
The excess risk was then halved and reduced to 1.12 by adjustment
for stage, and substantially reduced again to 1.04 by adjustment for
socioeconomic deprivation. Further adjustment for ethnicity made
no difference to the remaining risk, but the subsequent addition of
treatment reduced the hazard ratio to 1.00. These results indicate
that the main drivers of the excess mortality in NELCN women were
more advanced stage of disease at diagnosis and higher levels of
deprivation. We interpreted the small effect of treatment as a further
indicator of advanced disease stage, rather than of under-treatment.
Timing of excess risk of mortality
The Kaplan–Meier survival curves for NELCN women with breast
cancer compared with those in the rest of London are shown in
Figure 1A. The curves show an early divergence and then remain
parallel. The survival curves for patients still alive at 1 year after
the diagnosis are very similar (Figure 1B). This demonstrates that
the excess deaths in NELCN occur in the first year after diagnosis,
suggesting late diagnosis.
DISCUSSION
Summary of main findings
NELCN women with breast cancer more commonly presented with
advanced disease and lived in areas of higher socioeconomic
Table 1 Demographic and clinical characteristics of NELCN women
with breast cancer compared with the rest of London
Breast cases
NELCN Rest of London
Females No. 3773 % No. 17 059 %
Age group
00–49 850 22.5 4033 23.6
50–64 1252 33.2 6254 36.7
65–74 718 19.0 3029 17.8
75–84 664 17.6 2519 14.8
85+ 289 7.7 1224 7.2
SES
1 (Affluent) 216 5.7 2764 16.2
2 412 10.9 2968 17.4
3 606 16.1 3501 20.5
4 947 25.1 4276 25.1
5 (Deprived) 1592 42.2 3550 20.8
Stage
Stage 1 1038 27.5 4106 24.1
Stage 2–3 1274 33.8 6383 37.4
Stage 4 430 11.4 1115 6.5
Not known 962 25.5 5041 29.6
Treatment
Any surgery 3173 84.1 14 273 83.7
Any chemotherapy 906 24.0 4745 27.8
Any hormone 1118 29.6 5832 34.2
Any radiotherapy 958 25.4 5310 31.1
No treatment 332 8.8 1198 7.0
DCO 69 1.8 414 2.4
Ethnic group
White 2441 64.7 10 662 62.5
Asian 247 6.5 842 4.9
Black 245 6.5 1022 6.0
Mixed 15 0.4 63 0.4
Chinese 16 0.4 82 0.5
Other 69 1.8 561 3.3
Not known 740 19.6 3827 22.4
Abbreviations: DCO¼Death Certificate Only; NELCN¼North East London
Cancer Network; SES¼ Socioeconomic Status.
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deprivation, and these factors appear to be the main causes of their
higher mortality. The excess risk occurred in the first year after
diagnosis, suggesting, given the usual growth behaviour of breast
cancer, that women dying in this period had advanced disease
at diagnosis for which treatments have limited effectiveness in
extending the survival. This strongly suggests the need to develop
socially targeted strategies to promote earlier diagnosis. In this
regard, it is noteworthy that when only screen-detected breast
cancer was considered, there was no significant 5-year relative
survival difference between NELCN women and those in the rest of
London.
Comparison with other findings
Socioeconomic deprivation is well established to be associated
with lower breast cancer survival (Adams et al, 2004; Mullee et al,
2004; Downing et al, 2007; Cuthbertson et al, 2009), but can only
be a relatively crude indicator of other factors, including lower
education and awareness of breast cancer (Robb et al, 2009),
lower screening uptake (Moser et al, 2009), differing behaviour
in response to symptoms (Ramirez et al, 1999), competing
comorbidities and differing access to primary care and referral.
The recently published NHS ‘All Breast Cancer Report’ showed a
Table 2 Hazard ratios for breast cancer specific mortality for women diagnosed 2001–2005 in NELCN compared with the rest of London
Univariate Adjusted for age
Adjusted for
age, stage
Adjusted for age,
stage, deprivation
Adjusted for age, stage,
deprivation, ethnicity
Adjusted for age, stage,
deprivation, ethnicity,
treatment
Covariate
Hazard ratio
(95% confidence
interval)
Hazard ratio
(95% confidence
interval)
Hazard ratio
(95% confidence
interval)
Hazard ratio
(95% confidence
interval)
Hazard ratio
(95% confidence
interval)
Hazard ratio
(95% confidence
interval)
NELCN
Rest of Londona 1.00 1.00 1.00 1.00 1.00 1.00
NELCN 1.27 (1.15–1.41) 1.23 (1.11–1.37) 1.12 (1.01–1.24) 1.04 (0.94–1.16) 1.05 (0.94–1.17) 1.00 (0.89–1.11)
Age Group
o50a 1.00 1.00 1.00 1.00 1.00
50–64 0.88 (0.77–1.01) 1.13 (0.99–1.30) 1.16 (1.02–1.33) 1.19 (1.04–1.36) 1.27 (1.11–1.46)
65–74 1.73 (1.51–1.99) 1.82 (1.59–2.10) 1.87 (1.63–2.15) 1.92 (1.67–2.22) 2.47 (2.13–2.86)
75–84 2.90 (2.53–3.31) 2.83 (2.47–3.24) 2.90 (2.53–3.32) 3.02 (2.62–3.47) 4.23 (3.63–4.93)
85+ 7.72 (6.66–8.95) 6.54 (5.64–7.59) 6.66 (5.74–7.74) 6.95 (5.95–8.11) 9.19 (7.76–10.88)
Stage
Stage 1a 1.00 1.00 1.00 1.00
Stage 2–3 3.92 (3.18–4.82) 3.89 (3.16–4.78) 3.87 (3.14–4.76) 3.39 (2.75–4.17)
Stage 4 35.08 (28.53–43.13) 34.71 (28.23–42.68) 34.46 (28.02–42.37) 27.27 (22.11–33.63)
Not known 6.02 (4.89–7.40) 6.09 (4.95–7.49) 6.07 (4.93–7.46) 4.60 (3.73–5.67)
Quintile of deprivation
1 (Affluent)a 1.00 1.00 1.00
2 1.13 (0.96–1.34) 1.13 (0.95–1.34) 1.13 (0.95–1.34)
3 1.36 (1.16–1.59) 1.35 (1.15–1.58) 1.36 (1.16–1.60)
4 1.40 (1.20–1.63) 1.38 (1.18–1.60) 1.41 (1.21–1.65)
5 (Deprived) 1.53 (1.31–1.78) 1.49 (1.28–1.74) 1.45 (1.24–1.70)
Ethnic Group
Whitea 1.00 1.00
Asian 1.11 (0.89–1.37) 1.10 (0.89–1.36)
Black 1.22 (1.02–1.47) 1.16 (0.97–1.39)
Mixed 2.13 (1.26–3.63) 2.16 (1.27–3.67)
Chinese 0.35 (0.11–1.08) 0.38 (0.12–1.20)
Other 1.20 (0.93–1.56) 1.05 (0.81–1.37)
Not known 1.05 (0.95–1.17) 1.04 (0.93–1.15)
Had surgery
Na 1.00
Y 0.52 (0.46–0.57)
Had chemotherapy
Na 1.00
Y 1.54 (1.38–1.72)
Had radiotherapy
Na 1.00
Y 0.69 (0.62–0.76)
Had hormone therapy
Na 1.00
Y 0.74 (0.67–0.82)
Abbreviations: N¼ no; NELCN¼North East London Cancer Network; Y¼ yes. aBaseline category.
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significant 3.6% difference in 1-year relative survival between the
most deprived and most affluent symptomatic women diagnosed
in 2001–2002, but showed no significant difference in women with
screen-detected cancers. There was a 12.2% difference in 5-year
survival between the most deprived and most affluent quintiles for
symptomatic cancers and a much smaller one (6.6%) for screen-
detected cancers (National Health Service Cancer Screening
Programmes, 2009). More data on screening uptake and screening
histories would have been helpful. The similar proportion of
screen-detected cancer in NELCN and the rest of London suggests
similar screening uptake, although some differences might have
been expected given the higher deprivation in NELCN and the
strong association of deprivation with lower uptake in London
(Renshaw et al, 2010).
Presentation with more advanced disease has a major role in
explaining the lower survival of English women with breast cancer
(Richards, 2009). Excess mortality in English women compared
with Swedish and Norwegian women occurs mostly in the first
12 months after diagnosis, particularly in older patients. After this
time, the differences diminish, suggesting that later diagnosis,
rather than less effective treatment, in England might be
responsible (Møller et al, 2010). A similar mechanism of later
diagnosis is suggested for the excess 1-year mortality in NELCN
women of all ages. It is possible that lower survival in English
women could, in part, be driven by later diagnosis in areas of
higher socioeconomic deprivation as identified in London.
Implications
This study reinforces the importance of not making assumptions
about cause without investigation. It also shows how comparative
cancer survival figures can generate local initiatives. North East
London Cancer Network has set a target to improve breast cancer
survival to London levels by 2012 and a new Public Health
Advisory Board steers a programme to promote earlier diagnosis.
Initiatives include social marketing interventions to increase
screening uptake, encouraging all women with symptoms to
present early, audit of deaths within a year of diagnosis and an
education campaign to improve public awareness of early cancer
symptoms. Surveys will assess population breast cancer awareness
to evaluate the effect of these interventions. There is more research
on interventions to promote screening uptake (Bonfill Cosp et al,
2001) than on earlier diagnosis of symptomatic disease. Catalano
et al (2003) found that repeated breast cancer awareness
campaigns could promote earlier diagnosis. This investigation
emphasises the need to understand why socioeconomic depriva-
tion is associated with poor survival and to develop creative
methods to engage with local communities (Eilbert et al, 2009;
Lyon et al, 2009).
Limitations
Under ascertainment of better prognosis breast cancers could lead
to incorrect low relative survival figures. Three findings argue
against this: (1) breast cancer incidence in each quintile of
deprivation within NELCN was very similar to those in the rest of
South East England, (2) the breast screening programme did not
supply a large number of extra cases and (3) the number of cases
recorded by the Registry was similar to that within NELCN clinical
information systems. The staging data available for this study were
incomplete with 26–30% of cases unknown. Audit of network
clinical systems and medical records found that data were also
incomplete. Work on improved collection of staging and
comorbidity data at multi-disciplinary team meetings, and its
transfer to the Registry is underway.
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Figure 1 Kaplan–Meier survival estimates for NELCN women with
breast cancer compared with women in the rest of London, 2001–2005.
(A) 5-year survival. (B) Survival conditional on surviving the first year after
diagnosis.
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